Blood
Articles in this Issue
Safety of ravulizumab use in pregnancy: Insights from a global pharmacovigilance analysis
Abstract Introduction: Ravulizumab, a long-acting C5 complement inhibitor and second-generation analog of eculizumab, is approved for the tr...
The genetic landscape of lymphoma: Insights from a primary immunodeficiency NGS panel in lymphoma patients
Abstract Introduction: Primary immunodeficiencies (PID) are a heterogeneous group of rare genetic disorders that disrupt immunity, leading t...
Clinical presentation and prognosis in erdheim-chester disease: Analysis of an international cohort of 1044 patients within the ecdga network
Abstract Background Erdheim-Chester disease (ECD) is a very rare histiocytic/dendritic cell neoplasm driven by mutations...
Prognostic and therapeutic implications of the immune landscape in Mantle Cell Lymphoma
Abstract Background The comprehensive immune landscape of mantle cell lymphoma (MCL) remains incompletely characterized. Immune cells within...
Live-cell pick-seq (LiP-Seq): Interrogating ultra-rare Mantle Cell Lymphoma MRD after CD19-targeted CAR T-cell therapy
Abstract Many cancer therapies induce high response rates, with some resulting in “undetectable” disease as assessed using standard patholog...
Metabolic and genetic determinants of severe asparaginase toxicities in adolescent and young adult acute lymphoblastic leukemia.
Abstract Introduction. Asparaginase is a key component in the treatment of Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL...
In Vivo pan CAR therapy utilizing circular RNA for treatment of autoimmune diseases
Abstract Background/ Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies...
Relationship between salvage strategy and outcomes in patients with CBF or NPM1-mutated AML and first molecular relapse
Abstract Introduction: Patients with Core-Binding Factor (CBF) and NPM1-mutated acute myeloid leukemia (AML) can be monitored by quantitativ...
An exploratory study to evaluate the safety and efficacy of autologous CAR-T cells with dual targeting of BCMA and CD19 (FKC289 Injection) in subjects with relapsed or refractory systemic light chain amyloidosis
Abstract Background: Light-chain (AL) amyloidosis is a rare, life-threatening plasma-cell dyscrasia characterized by the...
Increasing guideline-based anti-emetic prophylaxis for chemotherapy-induced nausea/vomiting within a quaternary pediatric hospital
Abstract Introduction: Chemotherapy-induced nausea and vomiting (CINV) is a feared side effect of chemotherapy, contribu...
Temporal trends of mortality, associated conditions, hospitalizations, and costsrelated to hemophagocytic lymphohistiocytosis in the US.
Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a life threatening condition that triggers an inflammat...
Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD
Abstract Background: FLT3-ITD AML is associated with high relapse rates despite allogeneic hematopoietic stem cell transplantation (HCT). Po...
Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study
Abstract Introduction Management of DLBCL in older adults (OA) is challenging, requiring a personalized approach that accounts for age-relat...
Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials
Abstract Introduction: Combination therapies with venetoclax (VEN) + CD20 monoclonal antibody or Bruton tyrosine kinase inhibitors (BTKi) +...
Hydroxyurea use does not worsen age-related decline in blood counts in sickle cell disease
Abstract Introduction Advances in the care of individuals with sickle cell disease (SCD) have led to increased survival to adulthood. Accele...
Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study
Abstract Background: Mosunetuzumab (Mosun) is an off-the-shelf, CD20xCD3 T-cell engaging bispecific antibody that redirects T cells to elimi...
MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101
Abstract Introduction: The first-generation BCL2 inhibitor,venetoclax, is an effective treatment for CLL/SLL, but its usage may be limited b...
Association between progression-free survival and overall survival in mantle cell lymphoma: A trial-level surrogate endpoint analysis
Abstract Introduction: Survival outcomes of patients with mantle cell lymphoma (MCL) have substantially improved with the advent of novel th...
CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma
Abstract Background Chimeric antigen receptor (CAR) T-cell therapies have shown significant clinical benefit for patient...
Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study
Abstract Objective: This study aimed to characterize the disease profile, initial treatment approaches, and survival outcomes of patients wi...
Determinants of survival in primary cutaneous anaplastic large cell lymphoma (pcALCL): Analysis of a real-world pooled database
Abstract Background: Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) is a rare subtype of primary cutaneous T-...
Clia plus venetoclax for AML: Feasibility and efficacy in a hybrid community setting
Abstract Background: The addition of venetoclax (VEN) to purine-analog-based intensive chemotherapy has demonstrated safety and efficacy in...
Trial in progress: Pilot trial of olutasidenib maintenance post allogeneic hematopoietic cell transplantation in patients carrying IDH1 mutation with AML, MDS, or CMML
Abstract Study Rationale. Relapse remains a major cause of treatment failure following allogeneic hematopoietic cell transplantation (alloHC...
Efficacy of voxelotor in sickle cell disease: A comprehensive meta-analysis of hemoglobin response, hemolysis control, and clinical outcomes across four randomized controlled trials
Abstract Background: Voxelotor, a hemoglobin S polymerization inhibitor, was approved in 2019 for the management of sickle cell disease (SCD...
Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety
Abstract Introduction: BR is a widely used 1L regimen in FL; however, there remains a need for novel combination therapies that achieve deep...